Cargando…
TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma
The past decade has witnessed the gradual and steady progress of adoptive T cell therapy in treating various types of cancer. In combination with gemcitabine and carboplatin chemotherapy, we previously conducted a clinical trial, NCT00690872, to treat Epstein-Barr virus (EBV)-positive nasopharyngeal...
Autores principales: | Wang, Guoping, Mudgal, Poorva, Wang, Liuyang, Shuen, Timothy Wai Ho, Wu, Haiyang, Alexander, Peter B, Wang, Who-Whong, Wan, Ying, Toh, Han Chong, Wang, Xiao-Fan, Li, Qi-Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331028/ https://www.ncbi.nlm.nih.gov/pubmed/34377592 http://dx.doi.org/10.1080/2162402X.2021.1955545 |
Ejemplares similares
-
Tailoring precision immunotherapy: coming to a clinic soon?
por: Han, Shuting, et al.
Publicado: (2020) -
Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma
por: Hopkins, Richard, et al.
Publicado: (2021) -
Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma
por: Chia, Whay-Kuang, et al.
Publicado: (2014) -
T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma
por: Zhang, Yang, et al.
Publicado: (2020) -
A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs)
por: Han, Shuting, et al.
Publicado: (2020)